Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kezar Life Sciences Inc (NQ: KZR )

0.8283 +0.0073 (+0.89%)
Streaming Delayed Price Updated: 9:36 AM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kezar Life Sciences Inc

< Previous 1 2 3 Next >
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology’s Kidney Week 2022 Annual Meeting
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
From Kezar Life Science
Via Business Wire
Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Present at the William Blair Biotech Focus Conference
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Appoints Courtney Wallace to its Board of Directors
From Kezar Life Sciences
Via Business Wire
Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Present at the Jefferies London Healthcare Conference
From Kezar Life Sciences, Inc.
Via Business Wire
Oxford Finance Provides $50 Million Credit Facility to Kezar Life Sciences, Inc.
From Oxford Finance LLC
Via Business Wire
Kezar Reports Third Quarter Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar to Host Virtual Investor and Analyst Day on November 15, 2021
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces First Patient Dosed in Phase 1 Trial of KZR-261 in Advanced Solid Tumor Malignancies
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Appoints Gitanjali Jain as Vice President, Investor Relations and External Affairs
From Kezar Life Sciences, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.